Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.

By S. Hohnloser, K. Kuck, P. Dorian, R. Roberts, J. Hampton, R. Hatala, E. Fain, M. Gent, S. Connolly. New England Journal of Medicine, 2004

1,470 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/dd7cf0e16cbf9f4e66a9e13d54481879b5d8fac7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. G. Fonarow
2. T. Horwich
3. Rick A. Nishimura
4. J. Halperin
5. J. Januzzi
6. M. Creager
7. C. Yancy
8. M. Drazner

In Radiology, Nuclear Medicine and Imaging

1. M. Creager

Citations in the corpus

• 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the preventionof sudden cardiac death (2015, neutral): “Nonetheless, early defibrillator implantation after an infarction does not improve prognosis, probably due to competing causes of death.(274,275) Optimal revascularization and medical therapy (including betablockers, dual antiplatelet therapy and statins) and prevention and treatment of HF are recom”
• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, background): “symptoms while receiving GDMT, who have reasonable expectation of meaningful survival for more than 1 yeary (362,597,598).”
• ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. (2008, methodology): “08 DINAMIT (331) 2004 674 35 6 to 40 days after MI and impaired HRV 1.”